Moclobemide treatment of clozapine-induced hypersalivation: Pilot open study

Anatoly Kreinin, Chanoch Miodownik, Igor Libov, Diana Shestakova, Vladimir Lerner

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

OBJECTIVES: Clozapine-induced hypersalivation (CIHS) affects a mean of approximately 30% patients and is a troublesome adverse effect that leads to massive compliance problems in patients with schizophrenia. For the management of this distressing adverse effect, different pharmacological agents have been recommended, yet none of them have been proven to be effective. The aim of our study was to investigate moclobemide, a reversible monoamine oxidase inhibitor-A, as an additional possibility for controlling or at least minimizing CIHS. METHODS: We enrolled 14 patients with schizophrenia who experienced CIHS. Moclobemide (150-300 mg/d) was added to their conventional regular treatment during 14 days. Hypersalivation was assessed at the start of the treatment and at its end point by the 5-point Nocturnal Hypersalivation Rating Scale. RESULTS: Two thirds of the subjects who experienced CIHS have demonstrated a beneficial effect after the addition of moclobemide, whereas one third of them have been nonresponders. None of the patients had any adverse effects. CONCLUSIONS: We assume that moclobemide can be another additional and safe medication for the treatment of CIHS; however, more data, based on controlled studies, are needed.

Original languageEnglish
Pages (from-to)151-153
Number of pages3
JournalClinical Neuropharmacology
Volume32
Issue number3
DOIs
StatePublished - 1 May 2009

Keywords

  • Clozapine
  • Clozapine-induced hypersalivation
  • Moclobemide
  • Schizophrenia
  • Substitute benzamide
  • Treatment

Fingerprint

Dive into the research topics of 'Moclobemide treatment of clozapine-induced hypersalivation: Pilot open study'. Together they form a unique fingerprint.

Cite this